Steventon, Luke; Nicum, Shibani; Man, Kenneth; Dodwell, David; Wang, Zhe; Patel, Apini; Pickwell-Smith, Ben; ... Chambers, Pinkie; + view all Steventon, Luke; Nicum, Shibani; Man, Kenneth; Dodwell, David; Wang, Zhe; Patel, Apini; Pickwell-Smith, Ben; Wei, Li; Chambers, Pinkie; - view fewer (2025) Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: a population-based retrospective cohort study. ESMO Real World Data and Digital Oncology , 8 , Article 100143. 10.1016/j.esmorw.2025.100143.

Preview

Text Steventon_1-s2.0-S2949820125000323-main.pdf Download (597kB) | Preview

Abstract

Background and purpose: In advanced ovarian cancer, delayed time to chemotherapy (TTC) has been associated with poorer survival outcomes; evidence is conflicting, however. This study investigated the impact of patient demographic factors on TTC and assessed whether TTC was associated with 5-year overall survival. Materials and methods: A retrospective cohort study was conducted using English national data for women with advanced-stage ovarian cancer (IIB-IV), treated with primary debulking surgery (PDS) or interval debulking surgery (IDS) þ adjuvant carboplatin/paclitaxel chemotherapy between 1 January 2014 and 31 December 2019. Cox proportional hazards regression was used to compare the primary outcome of 5-year overall survival between patients treated within 6 weeks (0-42 days) or >6 weeks (>42 days) of surgery. Results: A total of 4619 patients were included. Of these, 42% (n ¼ 1940) received PDS and 58% (n ¼ 2679) IDS. Median TTC was 45 days [interquartile range (IQR) 37-55 days] for PDS and 34 days (IQR 27-42 days) for IDS. TTC 6 weeks was associated with 5-year survival in the IDS cohort (HR 1.18, 95% CI 1.06-1.33, P ¼ 0.003), but not in the PDS cohort (HR 1.04, 95% CI 0.90-1.21, P ¼ 0.6). A higher proportion of patients from the most socioeconomically deprived backgrounds waited >6 weeks (45%, n ¼ 291) compared with the least deprived (37%, n ¼ 398). Adjuvant chemotherapy was initiated in 72% of patients in London within 6 weeks compared with 47% in the North West. Conclusions: Median TTC exceeded 4-week guidance from the European Society of Medical Oncology. TTC >6 weeks was associated with reduced 5-year survival in patients treated with interval surgery, but not primary surgery. Regional disparities in TTC were observed.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item